

# Alcohol intake and bradyarrhythmia risk: a cohort study of 407 948 individuals

Samuel J. Tu <sup>1</sup>, Celine Gallagher<sup>1</sup>, Adrian D. Elliott<sup>1</sup>, Dominik Linz <sup>1</sup>,  
Bradley M. Pitman<sup>1</sup>, Jeroen M.L. Hendriks<sup>1,2</sup>, Dennis H. Lau<sup>1</sup>,  
Prashanthan Sanders <sup>1</sup>, and Christopher X. Wong<sup>1\*</sup>

<sup>1</sup>Centre for Heart Rhythm Disorders, University of Adelaide, Royal Adelaide Hospital, Adelaide SA 5000, Australia; and <sup>2</sup>Caring Futures Institute, College of Nursing and Health Sciences, Flinders University, Adelaide, Australia

Received 28 August 2021; editorial decision 18 January 2022; online publish-ahead-of-print 17 February 2022

## Aims

There is a paucity of epidemiological evidence on alcohol and the risk of bradyarrhythmias. We thus characterized associations of total and beverage-specific alcohol consumption with incident bradyarrhythmias using data from the UK Biobank.

## Methods and results

Alcohol consumption reported at baseline was calculated as UK standard drinks (8 g alcohol)/week. Bradyarrhythmia events were defined as sinus node dysfunction (SND), high-level atrioventricular block (AVB), and permanent pacemaker implantations. Outcomes were assessed through hospitalization and death records, and dose–response associations were characterized using Cox regression models with correction for regression dilution bias. We studied 407 948 middle-aged individuals (52.4% female). Over a median follow-up time of 11.5 years, a total of 8 344 incident bradyarrhythmia events occurred. Increasing total alcohol consumption was not associated with an increased risk of bradyarrhythmias. Beer and cider intake were associated with increased bradyarrhythmia risk up to 12 drinks/week; however, no significant associations were observed with red wine, white wine, or spirit intake. When bradyarrhythmia outcomes were analysed separately, a negative curvilinear was observed for total alcohol consumption and risk of SND, but no clear association with AVB was observed.

## Conclusion

In this predominantly White British cohort, increasing total alcohol consumption was not associated with an increased risk of bradyarrhythmias. Associations appeared to vary according to the type of alcoholic beverage and between different types of bradyarrhythmias. Further epidemiological and experimental studies are required to clarify these findings.

## Keywords

Alcohol • Atrioventricular block • Bradyarrhythmias • Risk factor • Sinus node disease • Pacemaker

## Introduction

The demand for permanent pacemaker (PPM) insertions is rising, and this growing trend has significant implications for healthcare resource planning worldwide.<sup>1,2</sup> Clinically significant sinus node dysfunction (SND) and high-level atrioventricular block (AVB) represent the most common indications for PPM implantation. These diseases are typically attributed to idiopathic fibrosis of the conduction system, largely thought to be age-related,<sup>3,4</sup> and with an increasingly elderly population, the burden of bradyarrhythmias is projected to increase.<sup>5</sup>

In recent years, there has been an increasing focus on the role of modifiable risk factors in the primary prevention of arrhythmias, particularly for atrial fibrillation.<sup>6</sup> However, with the exception of sleep apnoea treatment in the setting of nocturnal bradyarrhythmias, societal guidelines on the management of bradycardia have made few recommendations as to the management of modifiable risk factors for preventing disease.<sup>7</sup> This is despite a number of key modifiable risk factors already identified, including sleep apnoea, body mass index (BMI), blood pressure, and elevated fasting blood glucose.<sup>5,8,9</sup> Furthermore, few population-based studies have investigated the

\*Corresponding author. E-mail address: c.wong@adelaide.edu.au

© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com)

## What's new?

- Few studies have investigated the role of alcohol consumption as a risk factor for incident bradyarrhythmias.
- In this study of 407 948 middle-aged individuals participating in the UK Biobank study, increasing total alcohol consumption was not associated with an increased risk of bradyarrhythmias.
- Exploratory analyses also suggest that associations may differ depending on the type of beverage and bradyarrhythmia; these findings require confirmation in other cohorts and experimental studies.

role of lifestyle factors on bradyarrhythmia risk. We have previously demonstrated no association of physical activity and bradyarrhythmia risk, contrasting with the protective effects of regular physical activity seen in observational studies for other arrhythmias.<sup>10</sup> With regards to alcohol consumption, no significant association has previously been demonstrated with incident SND,<sup>5</sup> nor AVB.<sup>9</sup> Whether these studies have had sufficient statistical power to detect a more modest or non-linear relationship with alcohol remains uncertain. To our knowledge, the role of individual beverages in bradyarrhythmia risk has also yet to be studied, despite increasing research attention in this area and conflicting data in other arrhythmias.<sup>6</sup>

To provide further insights on the potential role of alcohol intake and bradyarrhythmias, we characterized associations of total and beverage-specific alcohol consumption with incident bradyarrhythmias using prospective cohort data from the UK Biobank.

## Methods

### Study population

We retrospectively analysed data from the UK Biobank, a prospective cohort study of ~500 000 community-dwelling individuals. The UK Biobank has ethical approval from the North West Multicentre Research Ethics Committee. UK Biobank aged 40–69 years were identified from National Health Service (NHS) records and were invited by mail to attend 1 of 22 assessment centres between 2006 and 2010 to participate in the study. At enrolment, participants completed a touchscreen questionnaire collecting information on sociodemographic, diet, lifestyle, reproductive, and environmental factors. Anthropometric measurements were measured using standard protocols, verbal interview was undertaken to ascertain medical comorbidities, and blood and urine samples were also taken. Since recruitment, participants have been followed for hospitalizations and mortality through linkage with NHS records and invited to complete a range of follow-up questionnaires and tests in person and online.

In the present analysis, bradyarrhythmias were defined as an abnormality in rate or rhythm resulting in a pathologically slow ventricular response and included: SND, second- and third-degree AVB, and PPM implantations excluding biventricular and cardioverter-defibrillator devices. For our primary analyses, we focused on incident cases of bradyarrhythmias and excluded participants that (i) had prior diagnosis of a bradyarrhythmia or had a previous or current PPM implanted; (ii) were ex-drinkers of alcohol (so as to reduce the effect of reverse causality as

these participants may have abstained from alcohol due to poor health); and (iii) were missing specific alcohol consumption data.

### Assessment of alcohol consumption

Participants that indicated current consumption of alcohol on the enrolment questionnaire were asked to indicate how much of each alcoholic beverage (beer/cider, red wine, white wine, and spirits) they consumed in an average week or month (Supplementary material online, Methods). To standardize estimates, we reported the average standard drinks consumed per week of each beverage type. In this analysis, one standard drink was defined as 8 g (10 mL) of alcohol, the size of a UK standard drink. Notably, definitions of a standard drink vary by country (e.g. a standard drink in the USA contains 14 g of alcohol).<sup>11</sup>

### Assessment of covariates

The following covariates were self-reported at baseline: age, sex, race, education, assessment centre attended, Townsend deprivation index, and smoking status. Total metabolic equivalent of task (MET) min/week was calculated from a modified International Physical Activity Questionnaire. Body mass index was measured according to a standard protocol. Comorbidities at baseline were identified from (i) self-report on the baseline questionnaire or standardized verbal interview at enrolment; (ii) hospital inpatient diagnosis codes; or (iii) hospital operation/procedure codes (Supplementary material online, Table S1).

### Assessment of outcomes

Incident cases of bradyarrhythmia were identified by the first occurrence of a relevant: (i) hospital inpatient diagnosis; (ii) hospital operation/procedure; or (iii) bradyarrhythmia-related death, as previously described (Supplementary material online, Methods and Table S2).<sup>10</sup>

### Statistical analysis

Baseline characteristics were presented by categories of total alcohol consumption and summarized as median and interquartile range (IQR) if continuous, and as frequencies and proportions if categorical. Comparisons were assessed using the Kruskal–Wallis and  $\chi^2$  tests as appropriate.

Cox proportional hazard models were used to assess the association between alcohol consumption and the first occurrence of bradyarrhythmia. Individuals were considered at risk from the date of enrolment into the UK Biobank, until the (i) date of incident bradyarrhythmia; (ii) date of death not contributed to by bradyarrhythmia; (iii) date lost to follow-up; or (iv) the end of available follow-up, whichever came first.

For alcohol consumption, we examined the total consumption, as well as consumption of each beverage type individually. To correct for regression dilution bias due to measurement error and within-person variability in consumption over time, we performed regression calibration utilizing re-survey measurements available from 12.1% of the participants to estimate long-term average alcohol consumption (Supplementary material online, Methods).<sup>12</sup>

Alcohol consumption was included in the model as restricted cubic splines with 4 knots placed at 5th, 35th, 65th, and 95th percentiles, defined *a priori*. The model was stratified by sex and adjusted for age, race (White, other, unknown), education (college or university degree, vocational qualifications, optional national exams at ages 17–18 years, national exams at age 16 years, none of the above, and unknown), assessment centre attended at baseline (1 of 22 centres), Townsend deprivation index (in quintiles), BMI, total MET-minutes/week, smoking status (never, past, current, and unknown), and the following comorbidities as time-updated covariates: hypertension, coronary artery disease, heart failure, valvular disease, atrial fibrillation, diabetes mellitus, hyperlipidaemia, sleep apnoea,

thyroid disease, and chronic kidney disease. Hospital inpatient diagnoses/operations were used to update the information. Missing values for BMI and total MET-minutes/week were handled using the indicator variable method. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated by general contrasts of regression coefficients, using the median values of covariates and 0 drink/week as the referent value.

A number of sensitivity analyses were conducted: (i) excluding participants with events that occurred in the first 1 and 2 years of follow-up so as to mitigate any potential effect of reverse causality; (ii) excluding participants with coronary artery disease, heart failure, valvular disease, and/or atrial fibrillation at baseline so as to mitigate any potential bias due to survivorship; (iii) performing complete case analyses instead of the indicator variable method; (iv) mutually adjusting for the consumption of other beverages in models for individual beverage consumption; and (v) including ex-drinkers in the analyses.

As exploratory analyses, we assessed for a differential effect of alcohol consumption by sex. An interaction term between alcohol consumption and these categories was included in the model, and likelihood ratio tests were performed with the nested model to identify significant interactions. We also performed analyses for each individual bradyarrhythmia outcome (SND, AVB, and PPM implantation). In these analyses, time to first respective outcome was considered without right censoring at the occurrence of other events.

The proportional hazards assumption was tested using Schoenfeld residuals and interaction with time, and no major violations were present after stratifying models by sex. A two-tailed *P* value was set at 0.05 for statistical significance. Analyses were performed using R, version 4.0.2.

## Results

The study population for the primary analyses consisted of 407 948 participants after stepwise exclusion of 1 903 UK Biobank participants with a history of bradyarrhythmias, 17 995 that were ex-drinkers, and 73 000 that were current consumers but did not have specific alcohol consumption information. A total of 8344 incident bradyarrhythmia events occurred over 4 590 804 person-years of follow-up with a median follow-up duration of 11.5 (IQR 10.7–12.3) years. The baseline characteristics of the study population are detailed in *Table 1*. Median total alcohol consumption in the study population was 8.0 (IQR 3.5–15.5) drinks/week, and 22 275 (5.5%) reported having never consumed alcohol. Participants consuming greater amounts of alcohol were younger, more likely male, White, and largely more comorbid. Ex-drinkers, who were not included in the primary analyses, were more likely older, female, non-White, and comorbid, and were also more likely to have a history of bradyarrhythmias. The distributions of total alcohol and individual beverage consumption in the study population are shown in [Supplementary material online, Figure S1](#). Participants whose alcohol consumption was predominantly beer/cider or spirit consumption were generally more comorbid than participants whose alcohol consumption was predominantly red or white wine consumption ([Supplementary material online, Table S3](#)).

For aggregate total alcohol consumption, increasing consumption was not associated with an increased risk of bradyarrhythmias (*Figure 1*). Negative point estimates were observed across the spectrum of consumption and confidence intervals generally crossed unity, though consumption of 0–7 drinks/week was associated with statistically significant estimates. For beer and cider intake, a positive

curvilinear association was observed with bradyarrhythmia risk, though statistically significant estimates were only observed with consumption between 0 and 12 drinks/week. No other clear beverage-specific associations were observed. Sensitivity analyses did not materially change the results ([Supplementary material online, Table S4](#)). Ex-drinkers had a similar risk of bradyarrhythmias compared to current and never drinkers (HR 1.03, 95% CI 0.93–1.15), and associations were similar when ex-drinkers were included in the analysis ([Supplementary material online, Figure S2](#)), or when never drinkers were excluded from the analysis ([Supplementary material online, Figure S3](#)). No statistically significant effect modification by sex was observed for total alcohol or individual beverages and bradyarrhythmia risk.

When individual bradyarrhythmia outcomes were studied, there were 694 incident SND, 2091 incident AVB, and 7725 incident PPM implantations. Disaggregation of bradyarrhythmia outcomes demonstrated contrasting associations with total alcohol consumption (*Figure 2*). A negative curvilinear or L-shaped association was observed for total alcohol consumption and risk of SND, and statistically significant estimates below unity were observed with consumption between 10 and 65 drinks/week. No significant association was present for total alcohol consumption and risk of AVB. The association of total alcohol consumption and PPM implantation was similar to that of the composite bradyarrhythmias outcome. Individual beverage associations demonstrated a potentially protective association against SND with increasing white wine intake, and a potentially harmful association for AVB with increasing beer and cider intake ([Supplementary material online, Figure S4](#)).

## Discussion

This is the largest study to our knowledge to characterize associations of total and beverage-specific alcohol consumption with incident bradyarrhythmias. Leveraging the prospective UK Biobank cohort, we studied 407 948 community-dwelling and mostly White British individuals and 8344 bradyarrhythmia events over a median follow-up of 11.5 years. The principal findings of our study are as follows:

- (1) Increasing total alcohol consumption was not associated with an increased risk of bradyarrhythmias.
- (2) While light-to-moderate beer and cider consumption appeared to be associated with an increased risk of bradyarrhythmias, other alcoholic beverages, including red wine, white wine, and spirits, did not clearly demonstrate any significant associations.
- (3) When bradyarrhythmia outcomes were analysed separately, we additionally observed a negative curvilinear or L-shaped association for total alcohol consumption and risk of SND.

Previous population-based studies investigating the characteristics and risk factors associated with incident bradyarrhythmias have been substantially smaller in size, and the focus of these studies has not specifically been on the potential role of alcohol consumption. These studies did not identify any significant linear association of alcohol consumption with incident disease.<sup>5,9</sup> In this study, allowing for any potential non-linear associations, we found no evidence for any increase in bradyarrhythmia risk with increasing total alcohol consumption. This contrasts with that seen for atrial fibrillation and sudden cardiac death, where heavy alcohol consumption is an established risk factor.<sup>6,13</sup> Although potentially divergent associations were seen

**Table 1** Baseline characteristics of the study population

Characteristics	Overall	Total alcohol consumption (UK standard drinks/week)			
		<7	7–14	15–28	>28
Number of participants	407 948 (100%)	179 602 (44.0%)	111 557 (27.3%)	84 255 (20.7%)	32 534 (8.0%)
Female	212 633 (52.1%)	122 944 (68.5%)	58 189 (52.2%)	27 076 (32.1%)	4 424 (13.6%)
Age (years)	58.3 (50.6, 63.7)	58.6 (50.6, 63.9)	58.2 (50.5, 63.6)	58.1 (50.8, 63.4)	57.8 (50.6, 63.2)
White race	385 193 (94.4%)	162 577 (90.5%)	108 409 (97.2%)	82 367 (97.8%)	31 840 (97.9%)
Body mass index (kg/m <sup>2</sup> ) <sup>a</sup>	26.6 (24.1, 29.6)	26.4 (23.8, 29.8)	26.3 (23.9, 29.1)	26.9 (24.6, 29.7)	27.7 (25.3, 30.5)
Current smokers	41 297 (10.1%)	12 975 (7.2%)	9 672 (8.7%)	11 179 (13.3%)	7 471 (23.0%)
Physical activity (MET-minutes/week) <sup>b</sup>	1 790 (819, 3550)	1 710 (775, 3470)	1 800 (857, 3490)	1 870 (873, 3600)	1 920 (834, 4160)
Comorbidities					
Hypertension	113 347 (27.8%)	47 998 (26.7%)	28 175 (25.3%)	25 009 (29.7%)	12 165 (37.4%)
Coronary artery disease	20 894 (5.1%)	8 818 (4.9%)	5 216 (4.7%)	4 732 (5.6%)	2 128 (6.5%)
Heart failure	1 931 (0.5%)	825 (0.5%)	470 (0.4%)	442 (0.5%)	194 (0.6%)
Valvular disease	4 361 (1.1%)	2 028 (1.1%)	1 171 (1.0%)	852 (1.0%)	310 (1.0%)
Atrial fibrillation	5 612 (1.4%)	2 153 (1.2%)	1 516 (1.4%)	1 369 (1.6%)	574 (1.8%)
Diabetes mellitus	19 951 (4.9%)	10 293 (5.7%)	4 265 (3.8%)	3 669 (4.4%)	1 724 (5.3%)
Hyperlipidaemia	55 606 (13.6%)	23 551 (13.1%)	13 819 (12.4%)	12 577 (14.9%)	5 659 (17.4%)
Thyroid disease	21 911 (5.4%)	13 031 (7.3%)	5 504 (4.9%)	2 697 (3.2%)	679 (2.1%)
Sleep apnoea	7 965 (2.0%)	3 307 (1.8%)	1 870 (1.7%)	1 722 (2.0%)	1 066 (3.3%)
Chronic kidney disease	1 261 (0.3%)	736 (0.4%)	265 (0.2%)	191 (0.2%)	69 (0.2%)
Alcohol consumption (UK standard drinks/week)					
Total alcohol	8.0 (3.5, 15.5)	3.0 (0.7, 4.9)	9.7 (8.2, 11.7)	18.7 (16.0, 22.3)	36.4 (31.2, 45.6)
Beer/cider	0 (0, 4.7)	0 (0, 0.7)	1.6 (0, 4.7)	4.7 (0, 12.5)	15.6 (3.1, 31.2)
Red wine	1.2 (0, 5.8)	0 (0, 2.3)	3.5 (0, 7.0)	7.0 (0, 11.7)	7.0 (0, 21.0)
White wine	0.2 (0, 2.7)	0 (0, 0.9)	0.9 (0, 3.7)	0.9 (0, 5.5)	0 (0, 5.5)
Spirits	0 (0, 0.7)	0 (0, 0)	0 (0, 1.5)	0 (0, 2.2)	0 (0, 3.7)

One standard drink is defined as 8 g alcohol, the size of a standard drink in the UK. Categorical variables are reported as *n* (%) and continuous variables are reported as median (Q1, Q3). All comparisons between quartiles were statistically significant.

MET-minutes, metabolic equivalent of task-minutes.

<sup>a</sup>Missing 2099 (0.5%).

<sup>b</sup>Missing 76 677 (18.8%).

with specific alcoholic beverages and bradyarrhythmia types, these are exploratory findings that warrant further study.


Interestingly, previous case reports have described AV blocks of varying degrees occurring after binge drinking episodes.<sup>14,15</sup> Small historic experimental reports in the setting of acute alcohol ingestion have also demonstrated prolongation of sinus node recovery, His-ventricular intervals, and QRS duration,<sup>16,17</sup> though in contrast, one study demonstrated improvements in AV conduction.<sup>18</sup> More recently, data from a large population of mostly young and healthy attendants of the 2015 Munich Oktoberfest, who undertook one-lead electrocardiogram (ECG) recordings and handheld breath alcohol measurement, did not demonstrate a significant association between blood alcohol concentration and PR interval, QRS duration, and QTc interval, though blood alcohol concentration was associated with an increase in heart rate.<sup>19</sup> The pattern of long-term alcohol consumption is likely to have distinct effects on the cardiac conduction system compared with the effects of acute ingestion. Investigations into potential mechanisms that may underlie both beneficial and adverse associations of alcohol in arrhythmogenesis continue to attract ongoing investigation, and the findings of this study

suggest a need for further experimental studies in the field of bradyarrhythmias.


This is the largest study to our knowledge to characterize the relationship between alcohol and incident bradyarrhythmias, and the first to study associations by beverage and sex. Furthermore, adjustment for measurement error and long-term variability via regression calibration has not been previously undertaken. Observational studies relying on single point estimates of exposure variables measured with error suffer from regression dilution bias, where effect estimates are biased towards the null.<sup>12</sup> Correction for such bias as in the present study allows for more accurate estimates of the associations of long-term alcohol exposure. Our analyses also excluded ex-drinkers to limit reverse causality, although analyses including these participants resulted in comparable trends.

## Limitations

Several limitations warrant discussion. These data are observational in nature, and despite extensive multivariate adjustment and robust sensitivity analyses, we cannot exclude the possibility of residual confounding and reverse causality. The diagnostic codes used in our



**Figure 1** Association of total and beverage-specific alcohol consumption and incident bradyarrhythmias. One standard drink is defined as 8 g alcohol, the size of a standard drink in the UK. Bradyarrhythmias in this study included sinus node dysfunction, second- and third-degree atrioventricular block, and permanent pacemaker implantations excluding biventricular and cardioverter-defibrillator devices. Shaded areas represent 95% confidence intervals.



**Figure 2** Association of total alcohol consumption and individual bradyarrhythmia outcomes. One standard drink is defined as 8 g alcohol, the size of a standard drink in the UK. Shaded areas represent 95% confidence intervals.

study to identify SND and AVB have not been validated specifically in the UK Biobank cohort; however, a validation study of similar diagnostic codes in the Danish National Patient Registry has demonstrated strong positive predictive values of 87%.<sup>20</sup> A number of SND and AVB events are likely coded under other diagnostic codes, including under the diagnosis of syncope, which would limit power rather than bias results. We did not include bundle branch blocks or other conduction diseases in our definition of bradyarrhythmias as they would not necessarily cause a pathologically slow ventricular response, though these conditions should be examined in future studies. We did not adjust for multiple testing; as we studied several

exposures and outcomes, our original findings must therefore be considered exploratory. Additionally, no data were available on participant's historic consumption patterns, including length and pattern of alcohol consumption. Drinking patterns and lifestyle characteristics vary by race and population; these findings thus require confirmation in different populations beyond our predominantly White British cohort. The representativeness of UK Biobank to general populations is also limited by the 'healthy volunteer' phenomenon; however, valid assessment of exposure–disease relationships is nonetheless widely generalizable and do not require participants to be representative of the population at large.

## Conclusions

In this predominantly White British cohort, increasing total alcohol consumption was not associated with an increased risk of bradyarrhythmias. Associations appeared to differ according to the type of alcoholic beverage and between different types of bradyarrhythmias. Further experimental and epidemiological studies in other cohorts are required to clarify these findings.

## Supplementary material

Supplementary material is available at *Europace* online.

## Acknowledgements

This research has been conducted using the UK Biobank Resource under application number 62306.

## Funding

C.G. was supported by a Postdoctoral Fellowship from the University of Adelaide. A.D.E. was supported by an Early Career Fellowship from the National Heart Foundation of Australia. D.L. was supported by the Beacon Research Fellowship from the University of Adelaide. B.M.P. was supported by a Postgraduate Scholarship from the Hospital Research Foundation. J.M.L.H. was supported by an Early Career Fellowship from the National Heart Foundation of Australia and the Derek Frewin Lectureship from the University of Adelaide. D.H.L. was supported by the Robert J. Craig Lectureship from the University of Adelaide. P.S. was supported by a Practitioner Fellowship from the National Health and Medical Research Council of Australia and by the National Heart Foundation of Australia. C.X.W. was supported by a Mid-Career Fellowship from the Hospital Research Foundation and a Postdoctoral Fellowship from the National Heart Foundation of Australia.

**Conflict of interest:** J.M.L.H. reports that the University of Adelaide has received on his behalf lecture and/or consulting fees from Medtronic and Pfizer/BMS. D.H.L. reports the University of Adelaide has received on his behalf lecture and/or consulting fees from Abbott Medical, Bayer, Biotronik, Boehringer Ingelheim, Medtronic, Microport, and Pfizer/BMS. P.S. reports having served on the advisory board of Medtronic, Abbott Medical, Boston Scientific, CathRx, and PaceMate. P.S. reports that the University of Adelaide has received on his behalf lecture and/or consulting fees from Medtronic, Abbott Medical, and Boston Scientific. P.S. reports that the University of Adelaide has received on his behalf research funding from Medtronic, Abbott Medical, Boston Scientific, and Microport. C.X.W. reports that the University of Adelaide has received on his behalf lecture, travel, and/or research funding from Abbott Medical, Bayer, Boehringer Ingelheim, Medtronic, Novartis, Servier, St Jude Medical, and Vifor Pharma. The other authors have nothing to disclose.

## Data availability

Access to the UK Biobank Resource is available to all *bona fide* researchers for all types of health-related research that is in the public interest.

## References

- Greenspon AJ, Patel JD, Lau E, Ochoa JA, Frisch DR, Ho RT et al. Trends in permanent pacemaker implantation in the United States From 1993 to 2009: increasing complexity of patients and procedures. *J Am Coll Cardiol* 2012;**60**: 1540–5.
- Westaway S, Nye E, Gallagher C, Tu SJ, Clarke N, Hanna-Rivero N et al. Trends in the use, complications, and costs of permanent pacemakers in Australia: a nationwide study from 2008 to 2017. *Pacing Clin Electrophysiol* 2021;**44**:266–73.
- Lev M. Anatomic basis for atrioventricular block. *Am J Med* 1964;**37**:742–8.
- Thery C, Gosselin B, Lekieffre J, Warembourg H. Pathology of sinoatrial node. Correlations with electrocardiographic findings in 111 patients. *Am Heart J* 1977;**93**:735–40.
- Jensen PN, Gronroos NN, Chen LY, Folsom AR, deFilippi C, Heckbert SR et al. Incidence of and risk factors for sick sinus syndrome in the general population. *J Am Coll Cardiol* 2014;**64**:531–8.
- Tu SJ, Gallagher C, Elliott AD, Linz D, Pitman BM, Hendriks JML et al. Risk thresholds for total and beverage-specific alcohol consumption and incident atrial fibrillation. *JACC Clin Electrophysiol* 2021;**7**:1561–1569.
- Kusumoto FM, Schoenfeld MH, Barrett C, Edgerton JR, Ellenbogen KA, Gold MR et al. 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Circulation* 2019;**140**: e382–482.
- Harbison J, O'Reilly P, McNicholas WT. Cardiac rhythm disturbances in the obstructive sleep apnea syndrome: effects of nasal continuous positive airway pressure therapy. *Chest* 2000;**118**:591–5.
- Kerola T, Eranti A, Aro AL, Haukilahti MA, Holkeri A, Juntila MJ et al. Risk factors associated with atrioventricular block. *JAMA Netw Open* 2019;**2**:e194176.
- Elliott AD, Linz D, Mishima R, Kadhim K, Gallagher C, Middeldorp ME et al. Association between physical activity and risk of incident arrhythmias in 402 406 individuals: evidence from the UK Biobank cohort. *Eur Heart J* 2020;**41**:1479–86.
- Kalinowski A, Humphreys K. Governmental standard drink definitions and low-risk alcohol consumption guidelines in 37 countries. *Addiction* 2016;**111**:1293–8.
- MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. *Lancet* 1990;**335**:765–74.
- Chiuvè SE, Rimm EB, Mukamal KJ, Rexrode KM, Stampfer MJ, Manson JE et al. Light-to-moderate alcohol consumption and risk of sudden cardiac death in women. *Heart Rhythm* 2010;**7**:1374–80.
- van Cleef AN, Schuurman MJ, Busari JO. Third-degree atrioventricular block in an adolescent following acute alcohol intoxication. *BMJ Case Rep* 2011; **2011**. <https://doi.org/10.1136/bcr.07.2011.4547>.
- Letonja M, Petrovic D. Complete atrioventricular block induced by alcohol abuse. *Pacing Clin Electrophysiol* 2003;**26**:2192–3.
- Ettlinger PO, Lyons M, Oldewurtel HA, Regan TJ. Cardiac conduction abnormalities produced by chronic alcoholism. *Am Heart J* 1976;**91**:66–78.
- Greenspon AJ, Schaal SF. The "holiday heart": electrophysiologic studies of alcohol effects in alcoholics. *Ann Intern Med* 1983;**98**:135–9.
- Gould L, Reddy CV, Becker W, Oh KC, Kim SG. Electrophysiologic properties of alcohol in man. *J Electrocardiol* 1978;**11**:219–26.
- Brunner S, Drobiesch C, Herbel R, Sinner MF. Effects of acute alcohol consumption on cardiac excitation, conduction, and repolarization: results from the Munich Beer Related Electrocardiogram Workup Study (MunichBREW). *Clin Res Cardiol* 2021;**110**:916–8.
- Sundbøll J, Adelborg K, Munch T, Frøsvøl T, Sørensen HT, Bøtker HE et al. Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study. *BMJ Open* 2016;**6**:e012832.